Psychopharmacology and the Ethics of Resource Allocation
Author:
- 3 January 1993
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 162 (1) , 23-29
Abstract
The introduction of clozapine to current psychiatric practice is considered against a background of potential problems of resource allocation posed by the development of a number of ‘budget-busting’ drugs. It would appear that clinicians may increasingly have to operate within a climate in which the rights of individual patients to expensive treatments will seem to be pitted against the abilities of their communities to afford such treatments. Both clinicians and pharmaceutical companies have roles in the development of such conflicts.Keywords
This publication has 34 references indexed in Scilit:
- What do 5HT re‐uptake inhibitors do in obsessive‐compulsive disorders?Human Psychopharmacology: Clinical and Experimental, 1991
- Coronary bypasses 10 years on.BMJ, 1991
- How to pay for expensive drugs.BMJ, 1991
- Working with clozapinePsychiatric Bulletin, 1991
- The Marketing of5-Hydroxytryptamine: Depression or Anxiety?The British Journal of Psychiatry, 1991
- Battle of the clotbusters.BMJ, 1991
- Schizophrenia: Basic, release, reactive and defect processesHuman Psychopharmacology: Clinical and Experimental, 1990
- The 'Neuroleptics' and the Oedipus effectJournal of Psychopharmacology, 1990
- Lessons from the Insulin Story in PsychiatryAustralian & New Zealand Journal of Psychiatry, 1987
- Changes in Schizophrenic Psychopathology and Ward Behaviour as a Function of Phenothiazine TreatmentThe British Journal of Psychiatry, 1965